Free Trial

Alkermes (ALKS) Competitors

Alkermes logo
$27.08 +0.57 (+2.13%)
As of 02:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ALKS vs. ABEO, MEDP, OMCL, AMN, UTHR, INCY, NBIX, BMRN, EXAS, and EXEL

Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), and Exelixis (EXEL). These companies are all part of the "medical" sector.

Alkermes vs. Its Competitors

Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abeona Therapeutics$400K719.83-$63.73M$0.708.02
Alkermes$1.56B2.87$367.07M$2.0813.02

In the previous week, Alkermes had 22 more articles in the media than Abeona Therapeutics. MarketBeat recorded 24 mentions for Alkermes and 2 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 1.77 beat Alkermes' score of 0.72 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Alkermes
9 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 6.9% of Abeona Therapeutics shares are held by insiders. Comparatively, 4.4% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alkermes has a net margin of 23.15% compared to Abeona Therapeutics' net margin of 0.00%. Abeona Therapeutics' return on equity of 89.05% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
Abeona TherapeuticsN/A 89.05% 45.64%
Alkermes 23.15%24.86%17.14%

Abeona Therapeutics currently has a consensus price target of $19.50, indicating a potential upside of 247.28%. Alkermes has a consensus price target of $41.85, indicating a potential upside of 54.50%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alkermes
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92

Abeona Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Summary

Alkermes beats Abeona Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALKS vs. The Competition

MetricAlkermesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.46B$3.10B$5.72B$10.27B
Dividend YieldN/A2.32%5.72%4.60%
P/E Ratio13.0021.2575.6826.46
Price / Sales2.87383.59493.40165.76
Price / Cash10.1744.4425.8129.90
Price / Book2.999.6112.836.31
Net Income$367.07M-$53.18M$3.29B$270.30M
7 Day Performance-2.75%0.50%0.32%2.03%
1 Month Performance-6.76%4.75%4.71%6.23%
1 Year Performance-2.68%10.09%68.73%28.08%

Alkermes Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
4.5622 of 5 stars
$27.09
+2.1%
$41.85
+54.5%
-4.1%$4.46B$1.56B13.001,800
ABEO
Abeona Therapeutics
4.128 of 5 stars
$6.70
-2.8%
$19.50
+191.0%
+2.5%$343.58M$3.50M9.5790Positive News
MEDP
Medpace
4.3183 of 5 stars
$492.09
+1.0%
$412.73
-16.1%
+41.2%$13.82B$2.11B36.595,900Positive News
OMCL
Omnicell
4.065 of 5 stars
$32.33
+0.7%
$46.71
+44.5%
-25.3%$1.48B$1.11B64.663,670Positive News
AMN
AMN Healthcare Services
4.4893 of 5 stars
$20.97
+0.6%
$28.25
+34.7%
-61.4%$803.61M$2.98B-2.702,968Short Interest ↓
UTHR
United Therapeutics
4.7959 of 5 stars
$394.62
-1.5%
$429.62
+8.9%
+18.9%$17.80B$2.88B15.401,305Positive News
Insider Trade
INCY
Incyte
4.7342 of 5 stars
$86.56
-0.1%
$82.53
-4.7%
+30.8%$16.90B$4.24B19.672,617Positive News
Analyst Downgrade
Short Interest ↓
NBIX
Neurocrine Biosciences
4.7678 of 5 stars
$143.80
-0.2%
$160.00
+11.3%
+14.9%$14.26B$2.36B42.541,800Positive News
BMRN
BioMarin Pharmaceutical
4.9586 of 5 stars
$56.38
-2.4%
$92.04
+63.3%
-37.4%$10.83B$2.85B16.733,040Positive News
Analyst Upgrade
Short Interest ↑
EXAS
Exact Sciences
4.772 of 5 stars
$53.89
+0.1%
$67.05
+24.4%
-18.5%$10.20B$2.76B-9.927,000Short Interest ↓
Analyst Revision
EXEL
Exelixis
4.7096 of 5 stars
$37.69
-0.5%
$44.06
+16.9%
+47.4%$10.15B$2.17B18.121,147Positive News
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:ALKS) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners